Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02355184 · ClinicalTrials.gov registry record · Phase 2
An Extension of Protocol PRO 140_CD01 Study
A Phase 2 study, sponsored by CytoDyn.
- Terminated
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT02355184 is a Phase 2 study that was terminated before completion, run by CytoDyn. The registered enrollment target is 20 participants.
The verdict
NCT02355184, a Phase 2 study, was terminated before completion, sponsored by CytoDyn.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
This is an extension of Protocol PRO 140\_CD 01 to further evaluate the long-term suppression of HIV-1 replication following substitution of stable combination antiretroviral therapy with a PRO 140 (Monoclonal CCR5 antibody) monotherapy in adult subjects with HIV-1 infection
Interventions
- DRUG PRO 140 350mg weekly subcutaneous (SC) injection.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2014-11-18 |
| Est. Completion | 2022-07-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02355184
The ClinicalTrials.gov registry entry for NCT02355184 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CytoDyn, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PRO 140 350mg weekly subcutaneous (SC) injection. is the first listed.
NCT02355184 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02355184 about?
NCT02355184 is a clinical study titled "An Extension of Protocol PRO 140_CD01 Study". This is an extension of Protocol PRO 140\_CD 01 to further evaluate the long-term suppression of HIV-1 replication following substitution of stable combination antiretroviral therapy with a PRO 140 (Monoclonal CCR5 antibody) monotherapy in adult subjects with HIV-1 infection
What is the current status of trial NCT02355184?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2014-11-18. Estimated completion is 2022-07-15.
What interventions are being tested in trial NCT02355184?
The interventions under investigation include: PRO 140 350mg weekly subcutaneous (SC) injection. (DRUG).
Who is sponsoring clinical trial NCT02355184?
This trial is sponsored by CytoDyn, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.